• Sulfo-NHS-Biotin for Secretome-Linked Cell Profiling

  2026-08-24

  Sulfo-NHS-Biotin enables selective, water-compatible labeling of cell-surface proteins and biomolecular amines. This guide explains how to use its chemistry as a complementary layer in secretion-to-transcriptome studies, with practical assay design principles grounded in SEC-seq.

• CLK2, BRCA1, and Platinum Resistance in Ovarian Cancer

  2026-08-24

  The reference study identifies CLK2 as an ovarian cancer determinant of platinum resistance and connects its activity to BRCA1 phosphorylation at Ser1423 and enhanced DNA damage repair. Its integrated tissue, cellular, mechanistic, and xenograft evidence provides a rationale for testing CLK2-directed sensitization strategies, while also defining important limits for translation into pharmacological workflows.

• Sulforaphane Workflows for Stress and Inflammation

  2026-08-23

  Sulforaphane supports complementary workflows for cancer chemoprevention, oxidative stress response studies, and inflammasome-driven inflammation. This guide translates cell and mouse evidence into practical assay designs, dose-selection strategies, and troubleshooting steps for reproducible research.

• Sulfo-NHS-Biotin for Reliable Cell Assays

  2026-08-22

  Learn how Sulfo-NHS-Biotin (SKU A8001) can add a controlled cell-surface protein measurement to viability, proliferation, and cytotoxicity workflows. This scenario-based guide covers reaction chemistry, compatibility, protocol parameters, data interpretation, and practical product-selection criteria.

• Galectin-1–FIP200 Axis in Hepatic Steatosis

  2026-08-21

  The reference study identifies galectin-1 as an upstream suppressor of hepatic autophagy that promotes steatosis, dyslipidemia, and insulin resistance through direct interaction with FIP200. Its combination of in vivo phenotyping, proteomics, binding analysis, structural mapping, and interaction-disrupting mutations provides a mechanistic framework for studying autophagy failure in metabolic liver disease.

• X-Gal for Reproducible β-Galactosidase Assays

  2026-08-20

  This scenario-based guide explains how X-Gal supports blue-white colony screening and β-galactosidase reporter workflows while preventing overinterpretation in viability or cytotoxicity assays. It covers assay compatibility, stock preparation, data interpretation, and vendor-selection criteria for SKU A2539.

• CKI 7 Dihydrochloride: A Translational CK1 Strategy

  2026-08-20

  A mechanistic and strategic framework for using CKI 7 dihydrochloride to interrogate CK1 biology, validate pathway-dependent phenotypes, and connect kinase perturbation to translational questions in Wnt signaling, circadian biology, apoptosis, and cancer research.

• LDN-193189: Selective ALK Inhibitor for BMP Research

  2026-08-19

  LDN-193189 is a selective ALK inhibitor that targets BMP type I receptors ALK2 and ALK3. Product data and a peer-reviewed corneal epithelial study support its use for BMP signaling pathway inhibition, while emphasizing that pathway-specific and cell-context controls are essential.

• ATRX-Deficient Glioma and RTK Inhibitor Sensitivity

  2026-08-19

  The reference study identifies ATRX deficiency as a context associated with increased sensitivity of high-grade glioma cells to multi-targeted receptor tyrosine kinase and PDGFR inhibitors. It also shows that combining these inhibitors with Temozolomide increases toxicity in ATRX-deficient models, supporting ATRX status as a factor for interpreting targeted-treatment studies rather than as a standalone clinical biomarker.

• Sulforaphane: Reliable Cell Assay Workflows

  2026-08-18

  Learn how Sulforaphane, SKU C4733, can support reproducible viability, proliferation, apoptosis, and oxidative-stress experiments. This scenario-driven guide connects product specifications with dose planning, assay controls, mechanistic interpretation, and vendor-selection criteria.

• Palmitic acid (N2456): Practical Protocol Guide

  2026-08-18

  Palmitic acid (SKU N2456) provides a characterized saturated long-chain fatty acid for solvent-controlled studies of lipid metabolism, protein palmitoylation, metabolic disorder research, and inflammation signaling. It is suitable for freshly prepared ethanol- or DMSO-based workflows, but not for direct aqueous dissolution or long-term storage of prepared solutions.

• PLGA Microspheres for Extended Corticosteroid Delivery

  2026-08-17

  The reference study developed PEGylated PLGA microspheres containing hydrocortisone 17-butyrate and used release modeling to distinguish surface desorption from diffusion-controlled delivery. Its optimized formulation combined micrometer-scale particles, high drug entrapment, and reduced burst release, providing a practical framework for designing longer-acting intra-articular corticosteroid systems.

• L-NMMA acetate: NOS Pathway Research

  2026-08-17

  L-NMMA acetate enables controlled, broad inhibition of nitric oxide synthase for pathway-causality studies in regenerative cell models. This workflow translates dental follicle cell findings into practical assay design, dose planning, and troubleshooting for biochemical, inflammation, and disease research.

• QSHXO, Autophagy, and Ferroptosis in MASLD

  2026-08-16

  A 2026 World Journal of Hepatology study identifies coordinated autophagy activation and ferroptosis suppression as a mechanistic basis for the protective effects of Qushi Huoxue ointment in a mouse model of metabolic associated steatotic liver disease. Its integrated use of histology, biochemical assays, mass spectrometry, network pharmacology, molecular validation, and transmission electron microscopy provides a useful framework for evaluating liver-directed interventions, while also highlighting important limits of model-based inference.

• Angiotensin II Workflows for Vascular Research

  2026-08-15

  Build reproducible hypertension, vascular remodeling, and abdominal aortic aneurysm experiments with a defined Angiotensin II peptide workflow. This guide connects acute GPCR signaling to chronic disease-model endpoints while showing how the latest targeted AAA nanomedicine research can sharpen assay selection and interpretation.

8558 records 1/571 page Next 12345 下5页 Last page